[
  {
    "ts": null,
    "headline": "Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specif",
    "url": "https://finnhub.io/api/news?id=05c206b4cf62c3aed7baee41fd60743e9bb7728bd4f4999600e43a30fc033ea4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772134200,
      "headline": "Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer",
      "id": 139238433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specif",
      "url": "https://finnhub.io/api/news?id=05c206b4cf62c3aed7baee41fd60743e9bb7728bd4f4999600e43a30fc033ea4"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Kings That Could Easily Keep The Growth Streak Alive",
    "summary": "2 Dividend Kings That Could Easily Keep The Growth Streak Alive",
    "url": "https://finnhub.io/api/news?id=0298c10a0b80f2d413fe93fc71dfcad40cb50ee692f4b7a1abc20c2ca9a50d90",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772127292,
      "headline": "2 Dividend Kings That Could Easily Keep The Growth Streak Alive",
      "id": 139240385,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0298c10a0b80f2d413fe93fc71dfcad40cb50ee692f4b7a1abc20c2ca9a50d90"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's Preliminary Data From Phase 1b Trial Of Pasritamig In Combination With Docetaxel In Participants With Metastatic Castration-Resistant Prostate Cancer Shows Consistent Safety Profile, Clinically Meaningful Efficacy",
    "summary": "Johnson &amp; Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in",
    "url": "https://finnhub.io/api/news?id=d762455440cf03af2c4d299533c062b5b8491803ba205694d8f828e58f18624a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772120262,
      "headline": "Johnson & Johnson's Preliminary Data From Phase 1b Trial Of Pasritamig In Combination With Docetaxel In Participants With Metastatic Castration-Resistant Prostate Cancer Shows Consistent Safety Profile, Clinically Meaningful Efficacy",
      "id": 139247846,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in",
      "url": "https://finnhub.io/api/news?id=d762455440cf03af2c4d299533c062b5b8491803ba205694d8f828e58f18624a"
    }
  },
  {
    "ts": null,
    "headline": "Judge Rejects Kenvue Bid To Dismiss Texas Attorney General's Lawsuit Over Marketing Of Tylenol",
    "summary": "- Reuters Citing Court Order",
    "url": "https://finnhub.io/api/news?id=60478374054b5deda38fbf908241cc071572c2a5594aa7c73beee909c816ca65",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772107465,
      "headline": "Judge Rejects Kenvue Bid To Dismiss Texas Attorney General's Lawsuit Over Marketing Of Tylenol",
      "id": 139247847,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "- Reuters Citing Court Order",
      "url": "https://finnhub.io/api/news?id=60478374054b5deda38fbf908241cc071572c2a5594aa7c73beee909c816ca65"
    }
  },
  {
    "ts": null,
    "headline": "United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team",
    "summary": "United Therapeutics Corporation's Q4/FY2025 surge: Tyvaso growth, PAH/IPF trial catalysts, and revenue targets to 2030. Click for this UTHR earnings update.",
    "url": "https://finnhub.io/api/news?id=07fa1f5f68a03b76cc7d177507cc7c0557d45dfc164dab8aa711259ead843482",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772105408,
      "headline": "United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team",
      "id": 139235885,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1058322802/image_1058322802.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "United Therapeutics Corporation's Q4/FY2025 surge: Tyvaso growth, PAH/IPF trial catalysts, and revenue targets to 2030. Click for this UTHR earnings update.",
      "url": "https://finnhub.io/api/news?id=07fa1f5f68a03b76cc7d177507cc7c0557d45dfc164dab8aa711259ead843482"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Completes Launch Of CEREGLIDE 42, CEREGLIDE 57 Aspiration Catheters, Including INNERGLIDE 7 Delivery Aid",
    "summary": "https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-catheter-portfolio-with-launch-of-cereglide-42-cereglide-57-and-innerglide-7",
    "url": "https://finnhub.io/api/news?id=b2b3bbd3741d2eca6c566577767f8dc8017d688b301118e3627ea388ac583961",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772095896,
      "headline": "Johnson & Johnson Completes Launch Of CEREGLIDE 42, CEREGLIDE 57 Aspiration Catheters, Including INNERGLIDE 7 Delivery Aid",
      "id": 139233664,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-catheter-portfolio-with-launch-of-cereglide-42-cereglide-57-and-innerglide-7",
      "url": "https://finnhub.io/api/news?id=b2b3bbd3741d2eca6c566577767f8dc8017d688b301118e3627ea388ac583961"
    }
  }
]